SMARCA4 and breast carcinoma: Reduction of BRG1 levels or interference with BRG1 catalytic function reduces breast cancer cell proliferation, and yet these slow proliferating cells are more sensitive to cytotoxic agents that preferentially target rapidly growing cells.